obinutuzumab,acalabrutinib,venetoclax
roche,astrazeneca,abbvie
['cll', 'obinu']
dr. ryan from present on 68 tx-naive pts w/ cll treated w/ acala/obinu/ven -&gt; tx stops at 15m if umrd cr and av cont'd to 24m if not. 43% in bm-umrd cr at cycle 16 (45% if tp53 aberrant) and 86% u-mrd at c16 overall. #ash22 #cllsm 
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????